The National Institute of Allergy and Infectious Diseases (NIAID) last week announced the launch of two phase 2 clinical trials of a candidate H7N9 influenza vaccine, one to assess different dosages with or without an adjuvant and the second to look at the adjuvanted vaccine's performance alongside a quadrivalent seasonal flu vaccine.
In an update on an ongoing intravenous saline bag shortage, US Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, said yesterday the situation is improving, and the agency expects that the problems will be resolved well before the next flu season begins.
It includes a profile of what such a vaccine would accomplish and the different research areas needed.
The Centers for Disease Control and Prevention (CDC) today ended its investigation into a multistate outbreak of Salmonella Montevideo linked to raw sprouts.
Japan's health ministry has given fast-track approval to a new flu antiviral with a different mechanism of action than neuraminidase inhibitors that offers a one-dose treatment option, the Wall Street Journal reported today.
The proposed law would direct $200 million a year for 5 years to research.
Adults born from 1958 to 1979 may have experienced a drop in protection against 2009 H1N1 during the 2015-16 flu season because of priming with other H1N1 viruses during their younger years, according to a group led by the US Centers for Disease Control and Prevention.
The findings add more weight to calls for more broadly protective flu vaccines.
About 11% of a population sampled in the Democratic Republic of the Congo (DRC) had Zaire Ebola virus (EBOV) immunoglobulin G antibodies, providing serological evidence of Ebola prevalence in populations not currently experiencing an Ebola outbreak.
The Trump administration is making no effort to prioritize game-changing flu vaccines, the experts say.